Format

Send to

Choose Destination
Medchemcomm. 2017 Jul 7;8(8):1720-1726. doi: 10.1039/c7md00222j. eCollection 2017 Aug 1.

Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells.

Author information

1
West China School of Public Health/No. 4 West China Teaching Hospital , Sichuan University , Chengdu , 610041 , Sichuan , P.R. China.
2
State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy , West China Hospital , Sichuan University , Chengdu , 610041 , Sichuan , P.R. China.
3
Department of Hepatobiliary and Pancreas Surgery , The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital) , Shenzhen , 518020 , Guangdong , P.R. China . Email: Yue_Zhang1025@yeah.net ; Tel: +86 0755 2553 3018.

Abstract

Human lactate dehydrogenase A (LDHA) has been identified as a potential therapeutic target in the area of cancer metabolism. Herein, we report the discovery of novel LDHA inhibitors through docking-based virtual screening and biological assays. The primary enzymatic assay suggested that compound 11 targeted LDHA with an IC50 value of 0.33 μM. The in vitro cytotoxic assay demonstrated that compound 11 reduced the growth of MG-63 cancer cells with an EC50 value of 3.35 μM. Finally, we found that compound 11 induced the apoptosis of MG-63 cancer cells in a dose dependent manner, upregulated the oxygen consumption rate (OCR), and decreased the lactate formation and extracellular acidification rate (ECAR) in MG-63 cancer cells. Collectively, our data suggested that compound 11 could be a promising lead for the development of potent LDHA inhibitors.

Supplemental Content

Full text links

Icon for Royal Society of Chemistry Icon for PubMed Central
Loading ...
Support Center